基于肿瘤免疫微环境的肝癌分子分型研究进展

doi:10.11904/j.issn.1002-3070.2021.06.014

Abstract

Abstract: Immunotherapy improves the overall treatment strategy of liver cancer. Its unique immune heterogeneity and high tolerance to immune microenvironment make immunotherapy enter the bottleneck stage.Therefore,it is necessary to classify molecular classifications of liver cancer patients who may benefit from immune checkpoint therapy.With the progress of next-generation sequencing technology,scientists have explored molecular classifications based on the abundance of infiltrating immune cells,the expression of immune checkpoints,multi-omics data,mutually exclusive mechanisms for immunosuppression and the heterogeneity of tumor microenvironment.It is not only the specific biological,molecular and clinicopathological characteristics of liver cancer associated with the tumor microenvironment,but it also shows the overlap with the molecular classifications of the transcriptome.It is beneficial to the diagnosis of liver cancer,the choice of treatment methods and the prediction of clinical outcomes,and promotes accurate individualized immunotherapy for liver cancer.

Key words: Hepatocellular carcinoma, Tumor immunological microenvironment, Molecular classifications, Immune checkpoint inhibitor

CLC Number:

R735.7

LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment[J]. Journal of Practical Oncology, 2021, 35(6): 557-561.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.06.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I6/557

References

1 Galle PR,Forner A,Llovet JM,et al.EASL clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2018,69(1):182-236.
2 Nishida N,Kudo M.Immune checkpoint blockade for the treatment of human hepatocellular carcinoma[J].Hepatol Res,2018,48(8):622-634.
3 Chew V,Lai L,Pan L,et al.Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses[J].Proc Natl Acad Sci U S A,2017,114(29):5900-5909.
4 徐洋,秦琪,赵红,等.肿瘤微环境异质性的研究进展[J].实用肿瘤学杂志,2017,31(3):258-261.
5 Lee JS,Chu IS,Heo J,et al.Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling[J].Hepatology,2004,40(3):667-676.
6 Chiang DY,Villanueva A,Hoshida Y,et al.Focal gains of VEGFA and molecular classification of hepatocellular carcinoma[J].Cancer Res,2008,68(16):6779-6788.
7 Hoshida Y,Nijman SM,Kobayashi M,et al.Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma[J].Cancer Res,2009,69(18):7385-7392.
8 Ahn SM,Haq F,Park I,et al.The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma[J].BMC Cancer,2018,18(1):571.
9 Maman S,Witz IP.A history of exploring cancer in context[J].Nat Rev Cancer,2018,18(6):359-376.
10 Sia D,Jiao Y,Martinez-Quetglas I,et al.Identification of an immune-specific class of hepatocellular carcinoma,based on molecular features[J].Gastroenterology,2017,153(3):812-826.
11 Ally A,Balasundaram M,Carlsen R,et al.Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J].Cell,2017,169(7):1327-1341.
12 Shimada S,Mogushi K,Akiyama Y,et al.Comprehensive molecular and immunological characterization of hepatocellular carcinoma[J].EBioMedicine,2019,40:457-470.
13 Kurebayashi Y,Ojima H,Tsujikawa H,et al.Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification[J].Hepatology,2018,68(3):1025-1041.
14 Tsujikawa H,Masugi Y,Yamazaki K,et al.Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness[J].Hum Pathol,2016,50:24-33.
15 Kim HD,Song GW,Park S,et al.Association between expression level of PD1 by tumor-Infiltrating CD8(+)T cells and features of hepatocellular carcinoma[J].Gastroenterology,2018,155(6):1936-1950.
16 Zhang Q,Lou Y,Yang J,et al.Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas[J].Gut,2019,68(11):2019-2031.
17 Geiger R,Rieckmann JC,Wolf T,et al.L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity[J].Cell,2016,167(3):829-842.
18 Fujita M,Yamaguchi R,Hasegawa T,et al.Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations[J].EBio Medicine,2020,53:102659.
19 Leman JKH,Sandford SK,Rhodes JL,et al.Multiparametric analysis of colorectal cancer immune responses[J].World J Gastroenterol,2018,24(27):2995-3005.
20 Taylor NA,Vick SC,Iglesia MD,et al.Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer[J].J Clin Invest,2017,127(9):3472-3483.
21 Vitale I,Manic G,Coussens LM,et al.Macrophages and metabolism in the tumor microenvironment[J].Cell Metab,2019,30(1):36-50.
22 Zheng C,Zheng L,Yoo JK,et al.Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing[J].Cell,2017,169(7):1342-1356.
23 Liu Z,Zhang Y,Shi C,et al.A novel immune classification reveals distinct immune escape mechanism and genomic alterations:implications for immunotherapy in hepatocellular carcinoma[J].J Transl Med,2021,19(1):5.
24 Garcia J,Hurwitz HI,Sandler AB,et al.Bevacizumab(Avastin(R))in cancer treatment:a review of 15 years of clinical experience and future outlook[J].Cancer Treat Rev,2020,86:102017.
25 Shen J,Ju Z,Zhao W,et al.ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade[J].Nat Med,2018,24(5):556-562.
26 Jiang H,Hegde S,Knolhoff BL,et al.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy[J].Nat Med,2016,22(8):851-860.
27 Gao Q,Zhu H,Dong L,et al.Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J].Cell,2019,179(2):561-577.
28 Ribas A,Dummer R,Puzanov I,et al.Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy[J].Cell,2017,170(6):1109-1119.
29 Lin Z,Lu D,Wei X,et al.Heterogeneous responses in hepatocellular carcinoma:the achilles heel of immune checkpoint inhibitors[J].Am J Cancer Res,2020,10(4):1085-1102.

[1]	YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 552-556.
[2]	JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 562-567.
[3]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[4]	ZHAO Haoran, LI Man, ZHANG Yubao. Research progress of hepatocellular carcinoma-related RNA binding protein [J]. Journal of Practical Oncology, 2021, 35(6): 576-579.
[5]	HE Ling, YAO Kecheng. Glycosylphosphatidylinositol transamidase and hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 458-461.
[6]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[7]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[8]	SHI Linna, SUI Hong. Progress and challenges of immune checkpoint inhibitor therapy for primary hepatocellular carcinoma [J]. Journal of Practical Oncology, 2020, 34(6): 560-564.
[9]	ZHOU Jian,CHEN Xuejian,WANG Wei,LI Ning,SUN Zhenyu,XU Lishan. The effect of silencing PRMT5 gene in biological behavior of human hepatocellular carcinoma cells [J]. Journal of Practical Oncology, 2020, 34(3): 208-213.
[10]	ZHANG Congyi, CUI Yifeng, LI Baobao, LIU Lianxin. Expression of cell division cycle 7 protein in hepatocellular carcinoma tissues and its effect on proliferation and invasion of hepatocellular carcinoma cells [J]. Journal of Practical Oncology, 2020, 34(2): 150-155.
[11]	CHEN Ziyin, BAI Yanchun, CAO Yangsen, LI Jian, XU Lili, ZHAO Qiushuang, WANG Yang. Dosimetry advantage of respiratory gating in the treatment of hepatocellular carcinoma with large segmentation [J]. Journal of Practical Oncology, 2019, 33(6): 536-539.
[12]	QU Yanfei, LIU Chao, WANG Bojun, FANG Lin, ZHANG Yanqiao. Expression of CSN6 gene in hepatocellular carcinoma tissues and its clinical significance [J]. Journal of Practical Oncology, 2019, 33(4): 328-333.
[13]	HE Wei, MU Qiming, WANG Gang, WAN Bo, LIAO Bo, YANG Juan. Expression of TACC3 and p53 protein in primary liver cancer and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 420-425.
[14]	SHI Xiaokang, DING, Youming. Research progress on the relationship between helicobacter and primary hepatocellular carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 271-274.
[15]	WEN Juanjuan, QU Bing, LIU Chao. Clinical significance of antithrombin Ⅲ gene expression in hepatocellular carcinoma tissues [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 117-121.

Research progress in molecular classification of liver cancer based on tumor immunological microenvironment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments